Please login to the form below

brentuximab vedotin

This page shows the latest brentuximab vedotin news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

At the tail-end of last year, Seattle and Astellas scored US approval for Padcev (enfortumab vedotin) for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form ... Padcev is Seattle's second marketed drug after its

Latest news

Seattle, Astellas bag speedy FDA okay for bladder cancer drug

Padcev (enfortumab vedotin) is indicated for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form of bladder cancer – in adults who have previously been treated with chemotherapy ... Approval comes well ahead of
AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE

England’s cost effectiveness watchdog says there are limited treatment options for people who have not responded to, or only have a temporary response to, brentuximab vedotin and cannot have stem
Seattle Genetics claims key US approval for Adcetris

Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than 40 years, with the US regulator approving it for use alongside ... Seattle has since turned its attention to its own TNBC
Takeda bags EU approval for Adcetris in lymphoma

CTCL). Adcetris (brentuximab vedotin) - a CD30-targeting antibody drug conjugate (ADC) - already has conditional approval in the EU for certain adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma, but

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Interview: Trevor Smith, Takeda

Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Principal Medical Writer: Varies on experience

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

PMHub

Add my company

Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...